APPROACHES TO TREATING MTDNA-BASED MITOCHONDRIAL DISEASE There are no generalizable rational treatments for patients with mitochondrial diseases due to deficiency in oxidative phosphorylation (OxPhos). We propose here to study pharmacological approaches to treat patients with mitochondrial diseases due to mutations in mtDNA, based on our discovery that specific agents can """"""""shift"""""""" the mutation load and/or rescue mitochondrial function in cells harboring mtDNA mutations. Specifically, we have found that the mTOR inhibitor rapamycin (sirolimus;trade name Rapamune) induces mitophagy in cells carrying homoplasmic mtDNA mutations, but does not do so in wild-type cells. Remarkably, we have now found that rapamycin treatment of heteroplasmic cells containing different pathogenic mtDNA mutations elicited a dramatic improvement in bioenergetic function, as did mdivi-1, an inhibitor of mitochondrial fission, but surprisingly, with no apparent reduction in mutant load. We now propose to follow up on these exciting results, in three ways. First, we will examine in greater detail the ability of rapamycin, mdivi-1, and other agents to restore mitochondrial function in heteroplasmic cells. Second, we will try to determine the mechanism by which functional rescue occurs, using both targeted (e,g, genetic knockdown) and unbiased (e.g. microarray) approaches. Third, we will assess the possibility of treating patients with rapamycin in a small clinical trial by first treating Dr. Hirano's mouse model of TK2 deficiency, which causes mtDNA depletion (synergy with Projects 1 and 3). If successful, the use of rapamycin or similar compounds could become the basis of the first rational treatment of mtDNA-based OxPhos diseases.

National Institute of Health (NIH)
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Research Program Projects (P01)
Project #
Application #
Study Section
Developmental Biology Subcommittee (CHHD)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Columbia University (N.Y.)
New York
United States
Zip Code
Wang, Dan; Li, Jia; Song, Chun-Qing et al. (2018) Cas9-mediated allelic exchange repairs compound heterozygous recessive mutations in mice. Nat Biotechnol 36:839-842
Hirano, Michio; Emmanuele, Valentina; Quinzii, Catarina M (2018) Emerging therapies for mitochondrial diseases. Essays Biochem 62:467-481
Raghavan, Neha S; Brickman, Adam M; Andrews, Howard et al. (2018) Whole-exome sequencing in 20,197 persons for rare variants in Alzheimer's disease. Ann Clin Transl Neurol 5:832-842
Barca, Emanuele; Ganetzky, Rebecca D; Potluri, Prasanth et al. (2018) USMG5 Ashkenazi Jewish founder mutation impairs mitochondrial complex V dimerization and ATP synthesis. Hum Mol Genet 27:3305-3312
Garone, Caterina; Taylor, Robert W; Nascimento, Andrés et al. (2018) Retrospective natural history of thymidine kinase 2 deficiency. J Med Genet 55:515-521
Kleiner, Giulio; Barca, Emanuele; Ziosi, Marcello et al. (2018) CoQ10 supplementation rescues nephrotic syndrome through normalization of H2S oxidation pathway. Biochim Biophys Acta Mol Basis Dis 1864:3708-3722
Siegmund, Stephanie E; Grassucci, Robert; Carter, Stephen D et al. (2018) Three-Dimensional Analysis of Mitochondrial Crista Ultrastructure in a Patient with Leigh Syndrome by In Situ Cryoelectron Tomography. iScience 6:83-91
Winawer, Melodie R; Griffin, Nicole G; Samanamud, Jorge et al. (2018) Somatic SLC35A2 variants in the brain are associated with intractable neocortical epilepsy. Ann Neurol 83:1133-1146
Lopez-Gomez, Carlos; Levy, Rebecca J; Sanchez-Quintero, Maria J et al. (2017) Deoxycytidine and Deoxythymidine Treatment for Thymidine Kinase 2 Deficiency. Ann Neurol 81:641-652
Siegmund, Stephanie E; Yang, Hua; Sharma, Rohit et al. (2017) Low-dose rapamycin extends lifespan in a mouse model of mtDNA depletion syndrome. Hum Mol Genet 26:4588-4605

Showing the most recent 10 out of 51 publications